已核实 DOI PubMed 相关产品: 9

Enhanced drug retention by anthracene crosslinked nanocomposites for bimodal imaging-guided phototherapy

Journal 2021 · IF 7.79 · 13(35): 14713-14722 · 发表于 2021 年 8 月 16 日
作者: Xiaoshan Fan,Lingjie Ke,Hongwei Cheng,Hu Chen,Zhiguo Li,Enyi Ye,Xian-Jun Loh,Yun-Long Wu,Gang Liu,Zibiao Li
阅读全文 在 PubMed 查看

摘要

Efficient drug delivery, multifunctional combined therapy and real-time diagnosis are the main hallmarks in the exploitation of precision nanomedicine. Herein, an anthracene-functionalized micelle containing a magnetic resonance imaging (MRI) contrast agent, upconversion nanoparticles (UCNPs) and the photosensitizer IR780 is designed to achieve sustained drug release and enhanced photothermal and photodynamic therapy. The polymer-coated hybrid micelle was achieved by crosslinking anthracene-dimer with UV light (λ > 300 nm), which is converted from near-infrared (NIR) irradiation upon UCNPs. Besides, the water-insoluble photosensitizer IR780 is introduced into the system to achieve efficient drug delivery and photothermal and photodynamic synergistic therapy. As a consequence of NIR-induced anthracene-dimer formation, the cross-linked nanocomposite shows sustained drug release, and the enhanced retention effect of IR780 could increase the photothermal conversion efficiency. Importantly, the incorporation of 2,2,6,6-tetramethyl-piperidineoxyl (TEMPO) as a nitroxide MRI contrast agent presents the potential for real-time diagnosis via nanotheranostics, and the fluorescence imaging of IR780 is applied to monitor drug distribution and metabolism. This strategy of sustained drug delivery by anthracene-dimer formation through the better penetration depth of NIR-II fluorescence provides an executable platform to achieve enhanced phototherapy in biomedical applications.

本研究中使用的阿拉丁产品

9 款产品在本文中被引用